Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israel-Headquartered RedHill Receives FDA Approval for H. Pylori Gastric Drug
Error: Contact form not found.
by Tzally Greenberg / CTech
Scientists at work in laboratory. Photo: Public domain via Wikicommons.
CTech – Nasdaq and Tel Aviv-listed pharmaceutical company RedHill Biopharma has received US Food and Drug Administration (FDA) clearance for its new pill TALICIA, which provides antibiotic treatment of Helicobacter pylori gastric infections, the company announced in a Monday filing. H. pylori is a type of gastric bacteria linked with increased risks of developing ulcers and stomach cancer.
In December, RedHill announced a successful clinical trial in which TALICIA, composed of the antibiotics rifabutin and amoxicillin, managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving standard care.
Founded in 2009, Tel Aviv-headquartered RedHill develops orally-administered medicine for gastrointestinal and inflammatory diseases. RedHill is traded at a market capitalization of $263 million after its price-per-share rose by 6.2% to $7.35 as of market close Monday.
RedHill intends to begin marketing TALICIA in the US during the first quarter of 2020 and to expand its sales team from 40 to 140 by the end of the year, according to the statement.
RedHill CEO Dror Ben-Asher said more than half of the world’s population is infected with H. pylori. “This type of bacteria is developing ever-greater resistance to drugs and has doubled its resistance between 2009 and 2013,” he said in an interview with Calcalist Monday. “That’s why we call it a super bacteria.”
